AIP
SNDX icon

Arrowpoint Investment Partners’s Syndax Pharmaceuticals SNDX Stock Holding History

Arrowpoint Investment Partners’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$279K Buy
+12,755
New +$265K 0.06% 94

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Arrowpoint Investment Partners's SNDX Position: Q2 2026 in Review

Arrowpoint Investment Partners opened a new position in Syndax Pharmaceuticals (SNDX) in Q2 2026: 12,755 shares worth $279K. The stake represents 0.06% of the portfolio and ranks #94 among its holdings.

242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Arrowpoint Investment Partners held 12,755 shares of Syndax Pharmaceuticals worth $279K as of Q2 2026.
  • Syndax Pharmaceuticals was a new Arrowpoint Investment Partners position in Q2 2026.
  • Syndax Pharmaceuticals made up 0.06% of Arrowpoint Investment Partners's portfolio in Q2 2026, its #94 holding.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.